Pfizer Completes Acquisition of Medivation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
UBS Reiterates Buy on Pfizer (PFE) Following a Meeting with Management
September 30, 2016 11:01 AM EDTUBS reiterated a Buy rating and $38.00 price target on Pfizer (NYSE: PFE) following a meeting with management. The main topics included the recent decision not to break up, M&A/BD strategy, expenses/operating leverage and CNS remaining an attractive therapeutic area for research.
A UBS analyst commented, "Without... More
